Deals In Depth: September 2016
Teva is the latest pharma taking a bet on the risky anti-nerve growth factor field in a $3 billion deal with Regeneron; Abbott divested its medical optics business to J&J for $4 billion. Device financing increased significantly, thanks to a $2 billion debt offering by Acelity/Kinetic Concepts.
You may also be interested in...
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.